Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial.

Eur J Endocrinol · 2021 · PMC7849376 · PMID 33539318

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although CAS responses were significantly improved in both groups at week 12 and 24, patients receiving TG showed a trend towards better CAS response than those receiving iv.MP, and this difference was significant ( Fig. 3A , B and Table 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.